Ann Inc. (NYSE:ANN): UBS believes that Ann’s omni-channel strategy provides an advantage over competitors, and that improved products like Ann Taylor and LOFT, mix shift, targeted promotional strategies, store remodels, and easier factory/outlet comps will serve as catalysts. The shares are Buy rated with a $40 price target.
Donaldson (NYSE:DCI): After Donaldson reported higher-than-expected fourth-quarter earnings per share, BMO Capital thinks that the company’s 2014 EPS guidance is probably too high. The firm believes that many of the company’s key end markets are growing at anemic rates, and it keeps an Underperform rating on the shares.
BioCryst (NASDAQ:BCRX): JMP Securities believes there could be significant demand for BioCryst’s oral kallikrein for the prevention of hereditary angioedema attacks if the drug demonstrates even modest efficacy. The firm thinks the company could become a takeover target in the future, and it recommends owning shares ahead of the release of Phase II data on the drug in the first quarter of next year. The price target has been raised to $8 from $5.
DSW (NYSE:DSW): After DSW reported better-than-expected results but maintained its guidance, William Blair thinks the company’s results were strong and keeps an Outperform rating on the shares.